Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Open accessAbstract
In the second part of this JACC State-of-the-Art Review, an early and sustainable preventive care plan is described for cardiometabolic-based chronic disease. This plan can improve cardiometabolic health by targeting early mechanistic events to decrease the risk for certain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibrillation). Included are various prevention modalities, intensive lifestyle interventions, pharmacotherapy and cardiovascular outcome trial evidence, and bariatric/metabolic procedures. A tactical approach of implementing published clinical practice guidelines/algorithms for early behavioral, adiposity, and dysglycemia targeting is emphasized, as well as relevant educational and research implications.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both prediabetes and metabolic syndrome confer increased risk of type 2 diabetes and cardiovascular disease.
“Both prediabetes and metabolic syndrome confer increased risk of T2D and CVD.802–804”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [804]
The Primary Prevention in Stage 2 CMBCD section describes progression from prediabetes to T2D and from metabolic drivers to early CVD. The Coronary Heart Disease section identifies metabolic syndrome as a CHD risk factor. Our copy does not state that metabolic syndrome increases the risk of developing T2D, so it does not support the full claim. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 180 · Cited by 113
Research works printed but not linked: 2
- [60]Norman AH, Tesser CD. Quaternary prevention: a balanced approach to demedicalisation. Br J Gen Pract 2019; 69: 28– 9. 30591604 PMC6301346
- [120]Neovius M, Narbro K, Keating C, Healthcare costs during 15 years after bariatric surgery for patients with different baseline glucose status. Lancet Diabetes Endocrinol 2015; 3: 855– 65. 26386667 PMC4880549
- Authors
- Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- University of Toronto (CA)
- NYU Langone Health (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Mechanick, Jeffrey I.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 75
- Issue
- 5
- Pages
- 539-555
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC8168371
- OpenAlex
- W3004488623
- Cited by
- 113
- References
- 180
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 16 · 2023: 15 · 2022: 25 · 2021: 10 · 2020: 10
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K23HL125991)
- Novo Nordisk
- Novartis
- Boehringer Ingelheim
- Sanofi
- Amgen
- Gilead Sciences
- Pfizer
- American Medical Association
- National Institutes of Health
- University of Alabama
- Merck
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- cardiometabolic disease, chronic disease prevention, cardiovascular disease prevention, coronary artery disease, heart failure, atrial fibrillation, lifestyle intervention, pharmacotherapy, cardiovascular outcome trials, bariatric surgery, metabolic surgery, adiposity, dysglycemia, behavioral interventions
- MeSH terms
- Animals, Cardiovascular Diseases, Chronic Disease, Humans, Preventive Health Services
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
